COMBINED SIROLIMUS AND NINTEDANIB THERAPY FOR VASCULAR LESIONS AND HEREDITARY HEMORRHAGIC TELANGIECTASIA

摘要

Methods and pharmaceutical compositions comprising one or more mTOR inhibitors such as sirolimus and one or more receptor tyrosine kinase inhibitors such as nintedanib are disclosed for treating vascular lesions and hereditary hemorrhagic telangiectasia.